4.60
0.18 (4.07%)
| Penutupan Terdahulu | 4.42 |
| Buka | 4.46 |
| Jumlah Dagangan | 128,460 |
| Purata Dagangan (3B) | 229,495 |
| Modal Pasaran | 878,682,560 |
| Harga / Jualan (P/S) | 23.35 |
| Harga / Buku (P/B) | 2.10 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Sep 2025 |
| Margin Operasi (TTM) | -384.43% |
| EPS Cair (TTM) | -3.63 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -29.90% |
| Nisbah Semasa (MRQ) | 0.920 |
| Aliran Tunai Operasi (OCF TTM) | -85.93 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -56.25 M |
| Pulangan Atas Aset (ROA TTM) | -63.60% |
| Pulangan Atas Ekuiti (ROE TTM) | -1,642.75% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Inventiva S.A. - American Depos | Menurun | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.0 |
| Purata | -0.63 |
|
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Institusi | 5.09% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Covestor Ltd | 30 Sep 2025 | 402 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 24.00 (HC Wainwright & Co., 421.74%) | Beli |
| Median | 16.50 (258.70%) | |
| Rendah | 11.00 (Guggenheim, 139.13%) | Beli |
| Purata | 17.00 (269.57%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 4.92 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 18 Nov 2025 | 11.00 (139.13%) | Beli | 4.18 |
| Wolfe Research | 06 Nov 2025 | 13.00 (182.61%) | Beli | 4.18 |
| HC Wainwright & Co. | 09 Oct 2025 | 24.00 (421.74%) | Beli | 5.53 |
| Canaccord Genuity | 30 Sep 2025 | 20.00 (334.78%) | Beli | 5.79 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |